BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006;25:2192-2202. [PMID: 16288209 DOI: 10.1038/sj.onc.1209248] [Cited by in Crossref: 116] [Cited by in F6Publishing: 118] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, Lan F, Liu Y, Yan S, Dong X, Cai L. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer. Cancer Epidemiology 2013;37:985-92. [DOI: 10.1016/j.canep.2013.08.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
2 Lu C, Liu Z, Klement JD, Yang D, Merting AD, Poschel D, Albers T, Waller JL, Shi H, Liu K. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. J Immunother Cancer 2021;9:e002624. [PMID: 34326167 DOI: 10.1136/jitc-2021-002624] [Reference Citation Analysis]
3 Ivanov SV, Ivanova AV, Goparaju CM, Chen Y, Beck A, Pass HI. Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochemical and Biophysical Research Communications 2009;382:514-8. [DOI: 10.1016/j.bbrc.2009.03.042] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
4 Seth D, Duly A, Kuo PC, McCaughan GW, Haber PS. Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation. World J Gastroenterol 2014; 20(36): 13088-13104 [PMID: 25278703 DOI: 10.3748/wjg.v20.i36.13088] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
5 Gimba ER, Tilli TM. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 2013;331:11-17. [PMID: 23246372 DOI: 10.1016/j.canlet.2012.12.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 7.6] [Reference Citation Analysis]
6 Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B. Immune microenvironment of gliomas. Lab Invest. 2017;97:498-518. [PMID: 28287634 DOI: 10.1038/labinvest.2017.19] [Cited by in Crossref: 148] [Cited by in F6Publishing: 150] [Article Influence: 29.6] [Reference Citation Analysis]
7 Wang B, Shi Z, Weber GF, Kennedy MA. Introduction of a new critical p value correction method for statistical significance analysis of metabonomics data. Anal Bioanal Chem 2013;405:8419-29. [PMID: 24026514 DOI: 10.1007/s00216-013-7284-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
8 Zhou X, Zimonjic DB, Park SW, Yang XY, Durkin ME, Popescu NC. DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. Int J Oncol 2008;32:1285-91. [PMID: 18497990 DOI: 10.3892/ijo_32_6_1285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 22] [Article Influence: 0.1] [Reference Citation Analysis]
9 Dos Anjos Pultz B, da Luz FA, de Faria PR, Oliveira AP, de Araújo RA, Silva MJ. Far beyond the usual biomarkers in breast cancer: a review. J Cancer 2014;5:559-71. [PMID: 25057307 DOI: 10.7150/jca.8925] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
10 Clemente N, Raineri D, Cappellano G, Boggio E, Favero F, Soluri MF, Dianzani C, Comi C, Dianzani U, Chiocchetti A. Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases. J Immunol Res 2016;2016:7675437. [PMID: 28097158 DOI: 10.1155/2016/7675437] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 9.7] [Reference Citation Analysis]
11 Yin M, Soikkeli J, Jahkola T, Virolainen S, Saksela O, Hölttä E. Osteopontin promotes the invasive growth of melanoma cells by activating integrin αvβ3 and down-regulating tetraspanin CD9. Am J Pathol 2014;184:842-58. [PMID: 24412090 DOI: 10.1016/j.ajpath.2013.11.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
12 Koro K, Parkin S, Pohorelic B, Yang AD, Narendran A, Egan C, Magliocco A. Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin in affecting breast cancer cell migration. Breast Cancer Res Treat 2011;126:73-83. [PMID: 20401631 DOI: 10.1007/s10549-010-0889-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
13 Weber GF. Metabolism in cancer metastasis. Int J Cancer 2016;138:2061-6. [DOI: 10.1002/ijc.29839] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 7.9] [Reference Citation Analysis]
14 Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 2010;10:71-81. [PMID: 20205680 DOI: 10.2174/156652410791065381] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 7.9] [Reference Citation Analysis]
15 Chan KK, Matchett KB, McEnhill PM, Dakir el H, McMullin MF, El-Tanani Y, Patterson L, Faheem A, Rudland PS, McCarron PA, El-Tanani M. Protein deregulation associated with breast cancer metastasis. Cytokine Growth Factor Rev 2015;26:415-23. [PMID: 26088937 DOI: 10.1016/j.cytogfr.2015.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
16 Shevde LA, Metge BJ, Mitra A, Xi Y, Ju J, King JA, Samant RS. Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin. J Cell Mol Med 2010;14:1693-706. [PMID: 19538464 DOI: 10.1111/j.1582-4934.2009.00821.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
17 Rodrigues MF, Obre E, de Melo FH, Santos GC Jr, Galina A, Jasiulionis MG, Rossignol R, Rumjanek FD, Amoêdo ND. Enhanced OXPHOS, glutaminolysis and β-oxidation constitute the metastatic phenotype of melanoma cells. Biochem J 2016;473:703-15. [PMID: 26699902 DOI: 10.1042/BJ20150645] [Cited by in Crossref: 53] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
18 Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, Vice C, Brustugun OT, Denko NC, Koong AC, Giaccia A, Le QT. The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One 2010;5:e9633. [PMID: 20224789 DOI: 10.1371/journal.pone.0009633] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
19 Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G, Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P, Kundu GC. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011;15:1113-26. [PMID: 21718227 DOI: 10.1517/14728222.2011.594438] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
20 Phillips RJ, Helbig KJ, Hoek KHVD, Seth D, Beard MR. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World J Gastroenterol 2012; 18(26): 3389-3399 [PMID: 22807608 DOI: 10.3748/wjg.v18.i26.3389] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
21 Tilli TM, Mello KD, Ferreira LB, Matos AR, Accioly MT, Faria PA, Bellahcène A, Castronovo V, Gimba ER. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 2012;72:1688-99. [PMID: 22495819 DOI: 10.1002/pros.22523] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
22 Ferreira LB, Tavares C, Pestana A, Pereira CL, Eloy C, Pinto MT, Castro P, Batista R, Rios E, Sobrinho-Simões M, Gimba ER, Soares P. Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. Oncotarget 2016;7:52003-16. [PMID: 27409830 DOI: 10.18632/oncotarget.10468] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
23 Miragliotta V, Pirone A, Donadio E, Abramo F, Ricciardi MP, Theoret CL. Osteopontin expression in healing wounds of horses and in human keloids. Equine Vet J 2016;48:72-7. [PMID: 25290989 DOI: 10.1111/evj.12372] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
24 Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14:2037-2044. [PMID: 20597997 DOI: 10.1111/j.1582-4934.2010.01115.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 119] [Article Influence: 9.7] [Reference Citation Analysis]
25 Johnson MD, Garrett CK, Bond JE, Coggan KA, Wolfgang MC, Redinbo MR. Pseudomonas aeruginosa PilY1 binds integrin in an RGD- and calcium-dependent manner. PLoS One 2011;6:e29629. [PMID: 22242136 DOI: 10.1371/journal.pone.0029629] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
26 Siddiqui AA, Jones E, Andrade D, Shah A, Kowalski TE, Loren DE, Chipitsyna G, Arafat HA. Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma. J Gastroenterol Hepatol 2014;29:1321-7. [PMID: 24548099 DOI: 10.1111/jgh.12561] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
27 Hoenerhoff MJ, Chu I, Barkan D, Liu ZY, Datta S, Dimri GP, Green JE. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene. 2009;28:3022-3032. [PMID: 19543317 DOI: 10.1038/onc.2009.165] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 5.5] [Reference Citation Analysis]
28 Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz A, Weber GF, Denhardt DT. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery. 2009;146:232-240. [PMID: 19628079 DOI: 10.1016/j.surg.2009.03.036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
29 Klement JD, Poschel DB, Lu C, Merting AD, Yang D, Redd PS, Liu K. Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression. Cancers (Basel) 2021;13:1006. [PMID: 33670921 DOI: 10.3390/cancers13051006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
30 Sun SJ, Wu CC, Sheu GT, Chang HY, Chen MY, Lin YY, Chuang CY, Hsu SL, Chang JT. Integrin β3 and CD44 levels determine the effects of the OPN-a splicing variant on lung cancer cell growth. Oncotarget 2016;7:55572-84. [PMID: 27487131 DOI: 10.18632/oncotarget.10865] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
31 Sun JY, Xu JM, Yan M, Ye F. Advances in understanding relationship between osteopontin and metastasis and recurrence of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2013; 21(16): 1498-1504 [DOI: 10.11569/wcjd.v21.i16.1498] [Reference Citation Analysis]
32 Blomberg Jensen M, Jørgensen A, Nielsen JE, Steinmeyer A, Leffers H, Juul A, Rajpert-De Meyts E. Vitamin D metabolism and effects on pluripotency genes and cell differentiation in testicular germ cell tumors in vitro and in vivo. Neoplasia 2012;14:952-63. [PMID: 23097629 DOI: 10.1593/neo.121164] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
33 Bandopadhyay M, Bulbule A, Butti R, Chakraborty G, Ghorpade P, Ghosh P, Gorain M, Kale S, Kumar D, Kumar S, Totakura KV, Roy G, Sharma P, Shetti D, Soundararajan G, Thorat D, Tomar D, Nalukurthi R, Raja R, Mishra R, Yadav AS, Kundu GC. Osteopontin as a therapeutic target for cancer. Expert Opinion on Therapeutic Targets 2014;18:883-95. [DOI: 10.1517/14728222.2014.925447] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 9.1] [Reference Citation Analysis]
34 Chakraborty G, Jain S, Patil TV, Kundu GC. Down-regulation of osteopontin attenuates breast tumour progression in vivo. J Cell Mol Med 2008;12:2305-18. [PMID: 18266970 DOI: 10.1111/j.1582-4934.2008.00263.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
35 da Fonseca Bastos ACS, da Silva Rezende AC, Ferreira LB, Blunck CB, Pombo-de-Oliveira MS, Emerenciano M, Gimba ERP. Osteopontin-c is overexpressed in KMT2A-AFF1 positive pediatric B-cell lymphoblastic leukemia when compared to those with ETV6-RUNX1". Leuk Res 2020;91:106316. [PMID: 32114371 DOI: 10.1016/j.leukres.2020.106316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Take Y, Nakata K, Hashimoto J, Tsuboi H, Nishimoto N, Ochi T, Yoshikawa H. Specifically modified osteopontin in rheumatoid arthritis fibroblast-like synoviocytes supports interaction with B cells and enhances production of interleukin-6. Arthritis Rheum 2009;60:3591-601. [DOI: 10.1002/art.25020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
37 Ferreira LB, Lima RT, Bastos ACSDF, Silva AM, Tavares C, Pestana A, Rios E, Eloy C, Sobrinho-Simões M, Gimba ERP, Soares P. OPNa Overexpression Is Associated with Matrix Calcification in Thyroid Cancer Cell Lines. Int J Mol Sci 2018;19:E2990. [PMID: 30274371 DOI: 10.3390/ijms19102990] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
38 Sun J, Feng A, Chen S, Zhang Y, Xie Q, Yang M, Shao Q, Liu J, Yang Q, Kong B, Qu X. Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1. Cell Mol Immunol 2013;10:176-82. [PMID: 23416968 DOI: 10.1038/cmi.2012.67] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
39 Plumer A, Duan H, Subramaniam S, Lucas FL, Miesfeldt S, Ng AK, Liaw L. Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer. BMC Cancer 2008;8:38. [PMID: 18237408 DOI: 10.1186/1471-2407-8-38] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
40 Bissonnette N, Dudemaine P, Thibault C, Robitaille G. Proteomic analysis and immunodetection of the bovine milk osteopontin isoforms. Journal of Dairy Science 2012;95:567-79. [DOI: 10.3168/jds.2011-4750] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
41 Hsiao TH, Lin CH, Lee TT, Cheng JY, Wei PK, Chuang EY, Peck K. Verifying expressed transcript variants by detecting and assembling stretches of consecutive exons. Nucleic Acids Res 2010;38:e187. [PMID: 20798177 DOI: 10.1093/nar/gkq754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Weber GF. The Phylogeny of Osteopontin-Analysis of the Protein Sequence. Int J Mol Sci 2018;19:E2557. [PMID: 30154395 DOI: 10.3390/ijms19092557] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
43 Inoue M, Shinohara ML. Intracellular osteopontin (iOPN) and immunity. Immunol Res 2011;49:160-72. [PMID: 21136203 DOI: 10.1007/s12026-010-8179-5] [Cited by in Crossref: 106] [Cited by in F6Publishing: 103] [Article Influence: 9.6] [Reference Citation Analysis]
44 Platzer G, Schedlbauer A, Chemelli A, Ozdowy P, Coudevylle N, Auer R, Kontaxis G, Hartl M, Miles AJ, Wallace BA, Glatter O, Bister K, Konrat R. The metastasis-associated extracellular matrix protein osteopontin forms transient structure in ligand interaction sites. Biochemistry 2011;50:6113-24. [PMID: 21609000 DOI: 10.1021/bi200291e] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
45 Albertsson AM, Zhang X, Leavenworth J, Bi D, Nair S, Qiao L, Hagberg H, Mallard C, Cantor H, Wang X. The effect of osteopontin and osteopontin-derived peptides on preterm brain injury. J Neuroinflammation 2014;11:197. [PMID: 25465048 DOI: 10.1186/s12974-014-0197-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
46 Fremder E, Munster M, Aharon A, Miller V, Gingis-Velitski S, Voloshin T, Alishekevitz D, Bril R, Scherer SJ, Loven D, Brenner B, Shaked Y. Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin. Int J Cancer 2014;135:270-81. [PMID: 24347266 DOI: 10.1002/ijc.28678] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
47 Wein M, Huelter-Hassler D, Nelson K, Fretwurst T, Nahles S, Finkenzeller G, Altmann B, Steinberg T. Differential osteopontin expression in human osteoblasts derived from iliac crest and alveolar bone and its role in early stages of angiogenesis. J Bone Miner Metab 2019;37:105-17. [PMID: 29327303 DOI: 10.1007/s00774-017-0900-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Viloria K, Hill NJ. Embracing the complexity of matricellular proteins: the functional and clinical significance of splice variation. Biomol Concepts 2016;7:117-32. [PMID: 27135623 DOI: 10.1515/bmc-2016-0004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
49 Shi Z, Mirza M, Wang B, Kennedy MA, Weber GF. Osteopontin-a alters glucose homeostasis in anchorage-independent breast cancer cells. Cancer Lett 2014;344:47-53. [PMID: 24157812 DOI: 10.1016/j.canlet.2013.10.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
50 Uhlmann ME, Georges RB, Boleij A, Eyol E, Kubarenko A, Adwan H, Berger MR. Influence of osteopontin expression on the metastatic growth of CC531 rat colorectal carcinoma cells in rat liver. Cancer Gene Ther 2011;18:795-805. [PMID: 21852811 DOI: 10.1038/cgt.2011.48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
51 Lin J, Myers AL, Wang Z, Nancarrow DJ, Ferrer-Torres D, Handlogten A, Leverenz K, Bao J, Thomas DG, Wang TD, Orringer MB, Reddy RM, Chang AC, Beer DG, Lin L. Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget 2015;6:22239-57. [PMID: 26068949 DOI: 10.18632/oncotarget.4161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
52 Hartung F, Wang Y, Aronow B, Weber GF. A core program of gene expression characterizes cancer metastases. Oncotarget 2017;8:102161-75. [PMID: 29254233 DOI: 10.18632/oncotarget.22240] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
53 Tang X, Li J, Yu B, Su L, Yu Y, Yan M, Liu B, Zhu Z. Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int J Biol Sci. 2013;9:55-66. [PMID: 23289017 DOI: 10.7150/ijbs.5280] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
54 Hu H, Liu Z, Liu C. Correlation of OPN gene expression with proliferation and apoptosis of ovarian cancer cells and prognosis of patients. Oncol Lett 2019;17:2788-94. [PMID: 30854053 DOI: 10.3892/ol.2019.9896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
55 Peng L, Guo Y, Zhou Y, Dai J, Wang H. Inhibition of Breast Cancer Metastasis and Angiogenesis by Antiosteopontin Single-Chain Fv-Fc Fusion Protein. Neoplasia 2009;11:509-19. [DOI: 10.1593/neo.81622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
56 Lamort AS, Giopanou I, Psallidas I, Stathopoulos GT. Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight. Cells 2019;8:E815. [PMID: 31382483 DOI: 10.3390/cells8080815] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
57 Wei T, Bi G, Bian Y, Ruan S, Yuan G, Xie H, Zhao M, Shen R, Zhu Y, Wang Q, Yang Y, Zhu D. The Significance of Secreted Phosphoprotein 1 in Multiple Human Cancers. Front Mol Biosci 2020;7:565383. [PMID: 33324676 DOI: 10.3389/fmolb.2020.565383] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Hartung F, Weber GF. RNA blood levels of osteopontin splice variants are cancer markers. Springerplus 2013;2:110. [PMID: 23543917 DOI: 10.1186/2193-1801-2-110] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
59 Sonnenberg-Riethmacher E, Miehe M, Riethmacher D. Periostin in Allergy and Inflammation. Front Immunol 2021;12:722170. [PMID: 34512647 DOI: 10.3389/fimmu.2021.722170] [Reference Citation Analysis]
60 Sivakumar S, Niranjali Devaraj S. Tertiary structure prediction and identification of druggable pocket in the cancer biomarker - Osteopontin-c. J Diabetes Metab Disord 2014;13:13. [PMID: 24401206 DOI: 10.1186/2251-6581-13-13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
61 Kamioka Y, Takakura K, Sumiyama K, Matsuda M. Intravital Förster resonance energy transfer imaging reveals osteopontin-mediated polymorphonuclear leukocyte activation by tumor cell emboli. Cancer Sci 2017;108:226-35. [PMID: 27960041 DOI: 10.1111/cas.13132] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
62 Lee H, Jin YC, Kim SW, Kim ID, Lee HK, Lee JK. Proangiogenic functions of an RGD-SLAY-containing osteopontin icosamer peptide in HUVECs and in the postischemic brain. Exp Mol Med 2018;50:e430. [PMID: 29350679 DOI: 10.1038/emm.2017.241] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
63 Zhang Y, Li Z. RNA binding proteins: Linking mechanotransduction and tumor metastasis. Cancer Lett 2021;496:30-40. [PMID: 33007411 DOI: 10.1016/j.canlet.2020.09.020] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Minai-tehrani A, Jiang H, Kim Y, Chung Y, Yu K, Kim J, Shin J, Hong S, Lee J, Kim H, Chang S, Park S, Kang BN, Cho C, Cho M. Suppression of tumor growth in xenograft model mice by small interfering RNA targeting osteopontin delivery using biocompatible poly(amino ester). International Journal of Pharmaceutics 2012;431:197-203. [DOI: 10.1016/j.ijpharm.2012.04.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
65 Hao C, Wang Z, Gu Y, Jiang WG, Cheng S. Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis. Biomed Res Int 2016;2016:7310694. [PMID: 27462610 DOI: 10.1155/2016/7310694] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
66 Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008;122:889-97. [PMID: 17960616 DOI: 10.1002/ijc.23204] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 6.4] [Reference Citation Analysis]
67 Ries A, Goldberg JL, Grimpe B. A novel biological function for CD44 in axon growth of retinal ganglion cells identified by a bioinformatics approach. J Neurochem 2007;103:1491-505. [PMID: 17760872 DOI: 10.1111/j.1471-4159.2007.04858.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
68 Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, Aszmann O, Ludvik B, Silberhumer GR, Prager G. Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology. 2008;149:1350-1357. [PMID: 18048491 DOI: 10.1210/en.2007-1312] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 6.5] [Reference Citation Analysis]
69 Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol 2014;37:131-41. [PMID: 24657887 DOI: 10.1016/j.matbio.2014.03.001] [Cited by in Crossref: 140] [Cited by in F6Publishing: 140] [Article Influence: 17.5] [Reference Citation Analysis]
70 Ortiz-martínez F, Sanmartín E, Pomares-navarro E, Pérez-balaguer A, Andrés L, Sánchez-payá J, Aranda FI, Lerma E, Peiró G. Osteopontin Regulates VEGFA and ICAM-1 mRNA Expression in Breast Carcinoma. American Journal of Clinical Pathology 2015;143:812-22. [DOI: 10.1309/ajcp6f2vndamsula] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
71 Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Würl P, Taubert H, Vordermark D. Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer 2010;10:132. [PMID: 20377868 DOI: 10.1186/1471-2407-10-132] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
72 Fok TC, Lapointe H, Tuck AB, Chambers AF, Jackson-Boeters L, Daley TD, Darling MR. Expression and localization of osteopontin, homing cell adhesion molecule/CD44, and integrin αvβ3 in pleomorphic adenoma, polymorphous low-grade adenocarcinoma, and adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:743-51. [PMID: 24237725 DOI: 10.1016/j.oooo.2013.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
73 Fnu G, Agrawal P, Kundu GC, Weber GF. Structural Constraint of Osteopontin Facilitates Efficient Binding to CD44. Biomolecules 2021;11:813. [PMID: 34070790 DOI: 10.3390/biom11060813] [Reference Citation Analysis]
74 Wolak T. Osteopontin - a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis 2014;236:327-37. [PMID: 25128758 DOI: 10.1016/j.atherosclerosis.2014.07.004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 9.9] [Reference Citation Analysis]
75 Pallero MA, Elzie CA, Chen J, Mosher DF, Murphy-Ullrich JE. Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis. FASEB J 2008;22:3968-79. [PMID: 18653767 DOI: 10.1096/fj.07-104802] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
76 Boguslawska J, Sokol E, Rybicka B, Czubaty A, Rodzik K, Piekielko-witkowska A. microRNAs target SRSF7 splicing factor to modulate the expression of osteopontin splice variants in renal cancer cells. Gene 2016;595:142-9. [DOI: 10.1016/j.gene.2016.09.031] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
77 Jin YC, Lee H, Kim SW, Kim ID, Lee HK, Lee Y, Han PL, Lee JK. Intranasal Delivery of RGD Motif-Containing Osteopontin Icosamer Confers Neuroprotection in the Postischemic Brain via αvβ3 Integrin Binding. Mol Neurobiol 2016;53:5652-63. [PMID: 26482372 DOI: 10.1007/s12035-015-9480-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
78 Tilli TM, Thuler LC, Matos AR, Coutinho-Camillo CM, Soares FA, da Silva EA, Neves AF, Goulart LR, Gimba ER. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol 2012;92:13-9. [PMID: 21963599 DOI: 10.1016/j.yexmp.2011.09.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
79 Kruger TE, Miller AH, Godwin AK, Wang J. Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. Crit Rev Oncol Hematol. 2014;89:330-341. [PMID: 24071501 DOI: 10.1016/j.critrevonc.2013.08.013] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 7.3] [Reference Citation Analysis]
80 Zduniak K, Ziolkowski P, Ahlin C, Agrawal A, Agrawal S, Blomqvist C, Fjällskog ML, Weber GF. Nuclear osteopontin-c is a prognostic breast cancer marker. Br J Cancer 2015;112:729-38. [PMID: 25625274 DOI: 10.1038/bjc.2014.664] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
81 Fan Y, Jalali A, Chen A, Zhao X, Liu S, Teli M, Guo Y, Li F, Li J, Siegel A, Yang L, Liu J, Na S, Agarwal M, Robling AG, Nakshatri H, Li BY, Yokota H. Skeletal loading regulates breast cancer-associated osteolysis in a loading intensity-dependent fashion. Bone Res 2020;8:9. [PMID: 32128277 DOI: 10.1038/s41413-020-0083-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
82 Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19:333-345. [PMID: 18952487 DOI: 10.1016/j.cytogfr.2008.08.001] [Cited by in Crossref: 439] [Cited by in F6Publishing: 424] [Article Influence: 31.4] [Reference Citation Analysis]
83 Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC. Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 2007;11:81-90. [PMID: 17150036 DOI: 10.1517/14728222.11.1.81] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
84 Butti R, Ghosh P, Totakura KVS, Venkata RNN, Nimma R, Kundu GC. Role of Osteopontin in Tumor Microenvironment: A New Paradigm in Cancer Therapy. In: Gandhi V, Mehta K, Grover R, Pathak S, Aggarwal BB, editors. Multi-Targeted Approach to Treatment of Cancer. Cham: Springer International Publishing; 2015. pp. 113-25. [DOI: 10.1007/978-3-319-12253-3_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal. 2011;5:111-122. [PMID: 21516514 DOI: 10.1007/s12079-011-0130-6] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 7.1] [Reference Citation Analysis]
86 Nishimichi N, Hayashita-Kinoh H, Chen C, Matsuda H, Sheppard D, Yokosaki Y. Osteopontin undergoes polymerization in vivo and gains chemotactic activity for neutrophils mediated by integrin alpha9beta1. J Biol Chem 2011;286:11170-8. [PMID: 21321126 DOI: 10.1074/jbc.M110.189258] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
87 Weber GF. Time and Circumstances: Cancer Cell Metabolism at Various Stages of Disease Progression. Front Oncol 2016;6:257. [PMID: 28018856 DOI: 10.3389/fonc.2016.00257] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
88 Hao C, Cui Y, Owen S, Li W, Cheng S, Jiang WG. Human osteopontin: Potential clinical applications in cancer (Review). Int J Mol Med 2017;39:1327-37. [PMID: 28440483 DOI: 10.3892/ijmm.2017.2964] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
89 Mirzaei A, Mohammadi S, Ghaffari SH, Nikbakht M, Bashash D, Alimoghaddam K, Ghavamzadeh A. Osteopontin b and c isoforms: Molecular Candidates Associated with Leukemic Stem Cell Chemoresistance in Acute Myeloid Leukemia. Asian Pac J Cancer Prev 2017;18:1707-15. [PMID: 28670893 DOI: 10.22034/APJCP.2017.18.6.1707] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
90 Weber GF. Molecular mechanisms of metastasis. Cancer Lett. 2008;270:181-190. [PMID: 18522865 DOI: 10.1016/j.canlet.2008.04.030] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 5.9] [Reference Citation Analysis]
91 Ortiz-martínez F, Perez-balaguer A, Ciprián D, Andrés L, Ponce J, Adrover E, Sánchez-payá J, Aranda FI, Lerma E, Peiró G. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. Human Pathology 2014;45:504-12. [DOI: 10.1016/j.humpath.2013.10.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
92 Nazneen F, Bai F. The Roles of Osteopontin in the Pathogenesis of West Nile Encephalitis. Vaccines (Basel) 2020;8:E748. [PMID: 33317005 DOI: 10.3390/vaccines8040748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Hao C, Cui Y, Lane J, Jia S, Ji J, Jiang WG. Distinctive Prognostic Value and Cellular Functions of Osteopontin Splice Variants in Human Gastric Cancer. Cells 2021;10:1820. [PMID: 34359989 DOI: 10.3390/cells10071820] [Reference Citation Analysis]
94 Ferreira LB, Eloy C, Pestana A, Lyra J, Moura M, Prazeres H, Tavares C, Sobrinho-Simões M, Gimba E, Soares P. Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma. Eur J Endocrinol 2016;174:551-61. [PMID: 26811408 DOI: 10.1530/EJE-15-0577] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
95 Delany AM. Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma. Cancer Biol Ther 2010;10:65-7. [PMID: 20657168 DOI: 10.4161/cbt.10.1.12452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
96 Walaszek K, Lower EE, Ziolkowski P, Weber GF. Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis. Br J Cancer 2018;119:1259-66. [PMID: 30353046 DOI: 10.1038/s41416-018-0228-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
97 Butti R, Kumar TVS, Nimma R, Banerjee P, Kundu IG, Kundu GC. Osteopontin Signaling in Shaping Tumor Microenvironment Conducive to Malignant Progression. Adv Exp Med Biol 2021;1329:419-41. [PMID: 34664250 DOI: 10.1007/978-3-030-73119-9_20] [Reference Citation Analysis]
98 Tilli TM, Ferreira LB, Gimba ER. Osteopontin-c mediates the upregulation of androgen responsive genes in LNCaP cells through PI3K/Akt and androgen receptor signaling. Oncol Lett 2015;9:1845-50. [PMID: 25789054 DOI: 10.3892/ol.2015.2939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
99 Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, Liu N, Fu Z, Kang C, Pu P, You Y. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol 2010;12:765-75. [PMID: 20511184 DOI: 10.1093/neuonc/noq006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
100 Moorman HR, Poschel D, Klement JD, Lu C, Redd PS, Liu K. Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation. Cancers (Basel) 2020;12:E3379. [PMID: 33203146 DOI: 10.3390/cancers12113379] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
101 Teoh ST, Lunt SY. Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond: Metabolism in cancer metastasis. WIREs Syst Biol Med 2018;10:e1406. [DOI: 10.1002/wsbm.1406] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
102 Nakamura KD, Tilli TM, Wanderley JL, Palumbo A Jr, Mattos RM, Ferreira AC, Klumb CE, Nasciutti LE, Gimba ER. Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells. Tumour Biol 2016;37:2655-63. [PMID: 26404131 DOI: 10.1007/s13277-015-4095-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
103 El-Tanani MK, Yuen HF, Shi Z, Platt-Higgins A, Buckley NE, Mullan PB, Harkin DP, Johnston PG, Rudland PS. Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells. Cancer Sci 2010;101:1354-60. [PMID: 20384635 DOI: 10.1111/j.1349-7006.2010.01561.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
104 Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007;26:6361-6371. [PMID: 17452979 DOI: 10.1038/sj.onc.1210463] [Cited by in Crossref: 124] [Cited by in F6Publishing: 128] [Article Influence: 8.3] [Reference Citation Analysis]
105 Shi Z, Wang B, Chihanga T, Kennedy MA, Weber GF. Energy metabolism during anchorage-independence. Induction by osteopontin-c. PLoS One 2014;9:e105675. [PMID: 25157961 DOI: 10.1371/journal.pone.0105675] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
106 Barathova M, Takacova M, Holotnakova T, Gibadulinova A, Ohradanova A, Zatovicova M, Hulikova A, Kopacek J, Parkkila S, Supuran CT, Pastorekova S, Pastorek J. Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype. Br J Cancer 2008;98:129-36. [PMID: 18026188 DOI: 10.1038/sj.bjc.6604111] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]
107 Wu J, Pungaliya P, Kraynov E, Bates B. Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry. Biomarkers 2012;17:125-33. [PMID: 22188260 DOI: 10.3109/1354750X.2011.643485] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
108 Reza S, Shaukat A, Arain TM, Riaz QS, Mahmud M. Expression of osteopontin in patients with thyroid dysfunction. PLoS One 2013;8:e56533. [PMID: 23437160 DOI: 10.1371/journal.pone.0056533] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
109 Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management. J Cell Biochem 2007;102:859-68. [DOI: 10.1002/jcb.21520] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 6.1] [Reference Citation Analysis]
110 Hahnel A, Wichmann H, Greither T, Kappler M, Würl P, Kotzsch M, Taubert H, Vordermark D, Bache M. Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients. BMC Cancer 2012;12:131. [PMID: 22471890 DOI: 10.1186/1471-2407-12-131] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
111 Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol 2010;5:1516-23. [PMID: 20689445 DOI: 10.1097/JTO.0b013e3181eba6bd] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
112 Briones-Orta MA, Avendaño-Vázquez SE, Aparicio-Bautista DI, Coombes JD, Weber GF, Syn WK. Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochim Biophys Acta Rev Cancer 2017;1868:93-108.A. [PMID: 28254527 DOI: 10.1016/j.bbcan.2017.02.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
113 Meckbach C, Tacke R, Hua X, Waack S, Wingender E, Gültas M. PC-TraFF: identification of potentially collaborating transcription factors using pointwise mutual information. BMC Bioinformatics 2015;16:400. [PMID: 26627005 DOI: 10.1186/s12859-015-0827-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
114 Shen H, Weber GF. The osteopontin-c splice junction is important for anchorage-independent growth. Mol Carcinog 2014;53:480-7. [PMID: 23359517 DOI: 10.1002/mc.21997] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
115 Johnston NI, El-Tanani MK. Osteopontin: a new role for a familiar actor. Breast Cancer Res 2008;10:306. [PMID: 19090971 DOI: 10.1186/bcr2199] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
116 Leung DT, Lim PL, Cheung TH, Wong RR, Yim SF, Ng MH, Tam FC, Chung TK, Wong YF. Osteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer Patients. PLoS One 2016;11:e0160412. [PMID: 27494141 DOI: 10.1371/journal.pone.0160412] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
117 Yosifov DY, Reufsteck C, Konstantinov SM, Berger MR. Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines. Leuk Res 2012;36:764-72. [PMID: 22421411 DOI: 10.1016/j.leukres.2012.02.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
118 Prat O, Bérenguer F, Steinmetz G, Ruat S, Sage N, Quéméneur E. Alterations in gene expression in cultured human cells after acute exposure to uranium salt: Involvement of a mineralization regulator. Toxicol In Vitro 2010;24:160-8. [PMID: 19654044 DOI: 10.1016/j.tiv.2009.07.035] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
119 Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007;67:330-40. [DOI: 10.1002/pros.20540] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 4.0] [Reference Citation Analysis]